Table 3.

Univariate and multivariate analyses for progression-free survival after bevacizumab administration in all cases included in this study

		Univariate analysis		Multivariate analysis
Variables		Hazard ratio (95% CI)	p-Value	Hazard ratio (95% CI)	p-Value
Method of bevacizumab administration	Group A vs. group B	0.47 (0.27–0.80)	< 0.01	0.53 (0.29–0.95)	0.03
Age (years)	≥ 50 vs. < 50	1.83 (1.01–3.50)	0.045	1.40 (0.73–2.81)	0.31
Drug combined with bevacizumab	Gemcitabine vs. other regimens	1.70 (0.95–3.25)	0.08
Histology	Serous carcinoma vs. other histology	0.73 (0.43–1.24)	0.24
Residual tumor at primary surgery	< 1 cm vs. ≥ 1 cm	0.94 (0.55–1.58)	0.82
FIGO stage	I, II vs. III, IV	0.98 (0.54–1.90)	0.95

Group A was defined as patients treated with weekly low-dose administration of bevacizumab

Group B was defined as patients treated with monthly high-dose administration of bevacizumab

CI confidence interval, FIGO International Federation of Gynecology and Obstetrics